PTC may delist Translarna in Germany

PTC Therapeutics Inc. (NASDAQ:PTCT) said it is considering removing Duchenne muscular dystrophy (DMD) drug Translarna ataluren from the German pharmacy ordering system after an arbitration process between the company and Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) "did not lead to an acceptable agreement" on the drug's pricing and reimbursement.

PTC announced the news after market close on Friday, but fell $3.33 (29%) to $7.99 on the day. The news was leaked just prior to market close. ...